Rafferty Asset Management Reduces Stake in BridgeBio Pharma

Institutional investor sells nearly 45,000 shares of biotech company

Mar. 3, 2026 at 5:47am

Got story updates? Submit your updates here. ›

Rafferty Asset Management LLC decreased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 22.8% during the 3rd quarter, according to the company's recent disclosure with the Securities & Exchange Commission. The fund now owns 151,990 shares of the company's stock, worth $7.9 million at the end of the quarter.

Why it matters

BridgeBio Pharma is a clinical-stage biotech company focused on developing treatments for genetic diseases and cancers. The reduction in Rafferty's stake could signal a shift in investor sentiment around the company's prospects, though the overall institutional ownership remains high.

The details

Rafferty Asset Management sold 44,792 shares of BridgeBio Pharma during the 3rd quarter, reducing its total position to 151,990 shares. The firm now owns about 0.08% of the company's outstanding stock. Other major institutional investors in BridgeBio include Vanguard Group, Franklin Resources, and Gilder Gagnon Howe & Co.

  • Rafferty Asset Management reduced its stake in the 3rd quarter of 2026.

The players

Rafferty Asset Management LLC

An institutional investment firm that has reduced its stake in BridgeBio Pharma.

BridgeBio Pharma, Inc.

A clinical-stage biopharmaceutical company focused on developing treatments for genetic diseases and cancers.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Rafferty's position in BridgeBio Pharma reflects shifting investor sentiment around the biotech company, though the overall institutional ownership remains high. This could signal potential volatility or uncertainty around BridgeBio's future prospects as it continues to advance its pipeline of experimental therapies.